The predictive value of EGFR status in non-small cell lung cancer patients treated with EGFR-TKIs.
10.3779/j.issn.1009-3419.2010.04.20
- Author:
Yuli WANG
1
;
Hongyu LIU
;
Jun CHEN
Author Information
1. Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenviroment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin 300052, China.
- Publication Type:Journal Article
- MeSH:
Carcinoma, Non-Small-Cell Lung;
drug therapy;
genetics;
Erlotinib Hydrochloride;
Humans;
Lung Neoplasms;
drug therapy;
genetics;
Protein Kinase Inhibitors;
therapeutic use;
Quinazolines;
therapeutic use;
Receptor, Epidermal Growth Factor;
antagonists & inhibitors;
genetics
- From:
Chinese Journal of Lung Cancer
2010;13(4):375-379
- CountryChina
- Language:Chinese
-
Abstract:
Epidermal growth factor receptor (EGFR) is a major molecular for target therapy. The epidermal growth factor receptor tyrosine kinase inhibitors (TKIs), gefitinib (Iressa) and erlotinib (Tarceva), are two prospective agents towards non-small cell lung cancer (NSCLC). Multi-center clinical studies showed that there were obvious differences between individuals by the treatment of EGFR-TKIs. EGFR status is the major factor that influences the outcome for the treatment by TKI. Exon mutations and amplification of EGFR molecule are the critical factors that predict good response to TKIs. On the other hand, KRAS mutations indicate the resistant to the TKIs.
